PCED1B and colorectal adenocarcinoma: We found that miR-633 inhibitor exacerbated the progression of colorectal adenocarcinoma, which was indicated by elevated cell proliferation (all p < 0.01, Figure 5a and b) and reduced apoptosis of SW620 and LoVo cells (both p < 0.01, Figure 5c), while co-transfection with sh-PCED1B-AS1 and miR-633 inhibitor partially eliminated the inhibitory impact of sh-PCED1B-AS1 on colorectal adenocarcinoma progression (p < 0.05, Figure 5a-c).